107 related articles for article (PubMed ID: 11754038)
1. Nonlinear pharmacokinetics of TAK-044, a new endothelin antagonist, in rats.
Takeuchi T; Tagawa Y; Hagihara K; Maeshiba Y; Yamashita K; Tsukuda R; Yoshimura Y
Biopharm Drug Dispos; 2001 Sep; 22(6):221-30. PubMed ID: 11754038
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interaction between TAK-044, a new endothelin antagonist, and ciclosporin in rats.
Maeshiba Y; Yamashita K; Tsukuda R; Yoshimura Y
Arzneimittelforschung; 2002; 52(9):664-8. PubMed ID: 12404880
[TBL] [Abstract][Full Text] [Related]
3. Disposition of TAK-044, a new endothelin antagonist, in rats and dogs.
Maeshiba Y; Takeuchi T; Kondo T; Yamashita K; Tsukuda R; Yoshimura Y
Arzneimittelforschung; 2002; 52(8):587-92. PubMed ID: 12236045
[TBL] [Abstract][Full Text] [Related]
4. Possible factor for nonlinear pharmacokinetics of TAK-603, a new antirheumatic agent, in rats.
Tagawa Y; Miwa K; Yamashita K; Tsukuda R; Yoshimura Y; Tanayama S; Tanigawara Y
Biopharm Drug Dispos; 1999 Jan; 20(1):11-8. PubMed ID: 10086833
[TBL] [Abstract][Full Text] [Related]
5. Carrier-mediated active transport of BQ-123, a peptidic endothelin antagonist, into rat hepatocytes.
Nakamura T; Hisaka A; Sawasaki Y; Suzuki Y; Fukami T; Ishikawa K; Yano M; Sugiyama Y
J Pharmacol Exp Ther; 1996 Aug; 278(2):564-72. PubMed ID: 8768705
[TBL] [Abstract][Full Text] [Related]
6. Effect of its demethylated metabolite on the pharmacokinetics of unchanged TAK-603, a new antirheumatic agent, in rats.
Tagawa Y; Miwa K; Tsukuda R; Yoshimura Y; Tanayama S; Tanigawara Y
Drug Metab Dispos; 1999 Apr; 27(4):495-501. PubMed ID: 10101145
[TBL] [Abstract][Full Text] [Related]
7. Kinetic study of the hepatobiliary transport of a new prostaglandin receptor agonist.
Imawaka H; Sugiyama Y
J Pharmacol Exp Ther; 1998 Mar; 284(3):949-57. PubMed ID: 9495854
[TBL] [Abstract][Full Text] [Related]
8. The Enhancement of Subcutaneous First-Pass Metabolism Causes Nonlinear Pharmacokinetics of TAK-448 after a Single Subcutaneous Administration to Rats.
Moriya Y; Kogame A; Tagawa Y; Morohashi A; Kondo T; Asahi S; Benet LZ
Drug Metab Dispos; 2019 Sep; 47(9):1004-1012. PubMed ID: 31201213
[TBL] [Abstract][Full Text] [Related]
9. Hepatobiliary transport of a nonpeptidic endothelin antagonist, (+)-(5S,6R,7R)-2-butyl-7-[2((2S)-2-carboxypropyl)-4-methoxyphenyl]-5-(3,4-methylenedioxyphenyl) cyclopentenol[1,2-b]pyridine-6-carboxylic acid: uptake by isolated rat hepatocytes and canalicular membrane vesicles.
Kobayashi N; Tani T; Hisaka A; Hara K; Yasumori T
Pharm Res; 2003 Jan; 20(1):89-95. PubMed ID: 12608541
[TBL] [Abstract][Full Text] [Related]
10. Optimal route of administration of mixed endothelin receptor antagonist (TAK-044) in liver transplantation.
Tanaka W; Yamanaka N; Onishi M; Ko M; Yamanaka J; Okamoto E
J Gastroenterol; 2000; 35(2):120-6. PubMed ID: 10680667
[TBL] [Abstract][Full Text] [Related]
11. Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury.
Li X; Zhong K; Guo Z; Zhong D; Chen X
Drug Metab Dispos; 2015 Nov; 43(11):1751-9. PubMed ID: 26276582
[TBL] [Abstract][Full Text] [Related]
12. Transporter-mediated hepatic uptake of ulifloxacin, an active metabolite of a prodrug-type new quinolone antibiotic prulifloxacin, in rats.
Yagi Y; Aoki M; Iguchi M; Shibasaki S; Kurosawa T; Kato Y; Tsuji A
Drug Metab Pharmacokinet; 2007 Oct; 22(5):350-7. PubMed ID: 17965518
[TBL] [Abstract][Full Text] [Related]
13. Hepatobiliary transport governs overall elimination of peptidic endothelin antagonists in rats.
Kato Y; Akhteruzzaman S; Hisaka A; Sugiyama Y
J Pharmacol Exp Ther; 1999 Feb; 288(2):568-74. PubMed ID: 9918560
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Transporters in the Hepatic Uptake of TAK-475 M-I, a Squalene Synthase Inhibitor, in Rats and Humans.
Ebihara T; Takeuchi T; Moriya Y; Tagawa Y; Kondo T; Moriwaki T; Asahi S
Drug Res (Stuttg); 2016 Jun; 66(6):316-23. PubMed ID: 27011383
[TBL] [Abstract][Full Text] [Related]
15. Role of endogenous endothelin in the extension of myocardial infarct size studied with the endothelin receptor antagonist, TAK-044.
Kojima M; Kusumoto K; Fujiwara S; Watanabe T; Fujino M
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S365-8. PubMed ID: 8587416
[TBL] [Abstract][Full Text] [Related]
16. Analysis of nonlinear hepatic clearance of a cyclopentapeptide, BQ-123, with the multiple indicator dilution method using the dispersion model.
Hisaka A; Nakamura T; Sugiyama Y
Pharm Res; 1999 Jan; 16(1):103-9. PubMed ID: 9950287
[TBL] [Abstract][Full Text] [Related]
17. Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury.
Otieno MA; Snoeys J; Lam W; Ghosh A; Player MR; Pocai A; Salter R; Simic D; Skaggs H; Singh B; Lim HK
Toxicol Sci; 2018 Jun; 163(2):374-384. PubMed ID: 28206647
[TBL] [Abstract][Full Text] [Related]
18. Carrier-mediated active transport of a novel thromboxane A(2) receptor antagonist [2-(4-chlorophenylsulfonylaminomethyl)indan-5-yl]acetate (Z-335) into rat liver.
Kawabata Y; Furuta S; Shinozaki Y; Kurimoto T; Nishigaki R
Drug Metab Dispos; 2002 May; 30(5):498-504. PubMed ID: 11950778
[TBL] [Abstract][Full Text] [Related]
19. Nonlinear pharmacokinetics of propafenone in rats and humans: application of a substrate depletion assay using hepatocytes for assessment of nonlinearity.
Komura H; Iwaki M
Drug Metab Dispos; 2005 Jun; 33(6):726-32. PubMed ID: 15743979
[TBL] [Abstract][Full Text] [Related]
20. A new endothelin receptor antagonist, TAK-044, shows long-lasting inhibition of both ETA- and ETB-mediated blood pressure responses in rats.
Ikeda S; Awane Y; Kusumoto K; Wakimasu M; Watanabe T; Fujino M
J Pharmacol Exp Ther; 1994 Aug; 270(2):728-33. PubMed ID: 8071866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
